Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors

PURPOSE: Omacetaxine mepesuccinate is a first-in-class cephalotaxine demonstrating clinical activity in chronic myeloid leukemia. A subcutaneous (SC) formulation demonstrated efficacy and safety in phase 1/2 trials in patients previously treated with ≥1 tyrosine kinase inhibitor. This study assessed...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Nemunaitis, John, Mita, Alain, Stephenson, Joe, Mita, Monica M., Sarantopoulos, John, Padmanabhan-Iyer, Swami, Nanda, Nisha, Gleich, Lyon, Benichou, Annie-Claude, Craig, Adam
Format: Artigo
Idioma:Inglês
Publicat: Springer-Verlag 2012
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3535355/
https://ncbi.nlm.nih.gov/pubmed/23053254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1963-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars